686 Results

People

  1. Giralt
    Giralt
  2. Usmani
    Usmani
  3. Landgren
    Landgren
  4. Lesokhin
    Lesokhin
  5. Landau
    Landau
  6. Mailankody
    Mailankody
  7. Hassoun
    Hassoun
  8. Hultcrantz
    Hultcrantz
  9. Shah
    Shah
  10. Shah
    Shah

Groups

  1. Department of Medicine (425)
  2. Hematologic Malignancies, Division of (378)
  3. Center for Hematologic Malignancies (353)
  4. Myeloma (190)
  5. Hematologic Malignancies Research (156)
  6. Bone Marrow Transplant (145)
  7. Survivorship Research (127)
  8. Sloan Kettering Institute Postdocs (86)
  9. GSK Faculty (76)
  10. Epidemiology and Biostatistics (65)
  1. "multiple myeloma"
Formats
  1. Journal Article (519)
  2. Review (86)
  3. Research Letter (23)
  4. Editorial (17)
  5. Meeting Abstract (15)
  6. Book Section (10)
  7. Correspondence (7)
  8. Guidelines (6)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (425)
  2. Hematologic Malignancies, Division of (378)
  3. Center for Hematologic Malignancies (353)
  4. Myeloma (190)
  5. Hematologic Malignancies Research (156)
  6. Bone Marrow Transplant (145)

More Groups

People
  1. Sergio Giralt (95)
  2. Saad Usmani (77)
  3. Carl Landgren (76)
  4. Alexander Lesokhin (66)
  5. Heather Landau (55)
  6. Sham Mailankody (55)

More People

Years
  1. 2025 (34)
  2. 2024 (83)
  3. 2023 (85)
  4. 2022 (49)
  5. 2021 (25)
  6. 2020 (47)

More Years

Publications
  1. Blood (37)
  2. Clinical Lymphoma, Myeloma and Leukemia (34)
  3. Biology of Blood and Marrow Transplantation (33)
  4. Leukemia and Lymphoma (21)
  5. Blood Cancer Journal (20)
  6. British Journal of Haematology (20)

More Publications

Publishers
  1. Elsevier Inc. (124)
  2. Nature Publishing Group (84)
  3. American Society of Hematology (48)
  4. Springer (34)
  5. John Wiley & Sons (30)
  6. Taylor & Francis Group (26)

More Publishers

Results (686)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma
    Journal Article

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: Findings from the MASTER and GRIFFIN trials
    Journal Article

    Chhabra, S.; Callander, N.; Watts, N. L.; Costa, L. J.; Thapa, B.; Kaufman, J. L.; Laubach, J.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Prevalence of smoldering multiple myeloma based on nationwide screening
    Journal Article

    Thorsteinsdóttir, S.; Gíslason, G. K.; Aspelund, T.; Rögnvaldsson, S.; Óskarsson, J. Þ; Sigurðardóttir, G. Á; Þórðardóttir, Á R.; Viðarsson, B.; Önundarson, P. T.; Agnarsson, B. A.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: Phase 1 UNIVERSAL trial interim results
    Journal Article

    Mailankody, S.; Matous, J. V.; Chhabra, S.; Liedtke, M.; Sidana, S.; Oluwole, O. O.; Malik, S.; Nath, R.; Anwer, F.; Cruz, J. C.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma
    Research Letter

    D’Souza, A.; Brazauskas, R.; Teng, B. Q.; Yun, G.; Uttley, H.; Dong, J.; Dwinell, M. B.; Pasquini, M. C.; Giralt, S.; Landau, H.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Ide-cel or standard regimens in relapsed and refractory multiple myeloma
    Journal Article

    Rodriguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial
    Journal Article

    Dimopoulos, M. A.; Oriol, A.; Nahi, H.; San-Miguel, J.; Bahlis, N. J.; Usmani, S. Z.; Rabin, N.; Orlowski, R. Z.; Suzuki, K.; Plesner, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: A prospective observational cohort study
    Journal Article

    Korde, N.; Tavitian, E.; Mastey, D.; Lengfellner, J.; Hevroni, G.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; more...
    eClinicalMedicine (2023)

    Fulltext@MSK | Save
  • Plasma cell neoplasms and related entities—Evolution in diagnosis and classification
    Review

    Fend, F.; Dogan, A.; Cook, J. R.
    Virchows Archiv (2023)

    Fulltext@MSK | Save
  • Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: Part 3 of the open-label, multicenter, phase 1b PAVO study
    Research Letter

    Nahi, H.; Usmani, S. Z.; Mateos, M. V.; van de Donk, N. W. C. J.; Oriol, A.; Plesner, T.; Bandyopadhyay, N.; Hellemans, P.; Tromp, B.; Nnane, I.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save